Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Can you give examples of any other biotech company have 96 news releases in the past 52 weeks?
9 pr's this month and the stock does nothing
You see these announcements and then you sit and say, why didn't the stock price move? And I'm telling you why it didn't move and I'm telling you why it wont move.
What do any of those questions have to do with what I posted?
I am optimistic for cancer, pessimistic for covid.
I will remind you when we trade
The stock will drop like SESN after they filled
the movie is the company story
this obsession with covid pumping is not going to benefit any of us.
What will be the next scam for this stock? Possibly toothpaste that prevents the coronavirus?
I think the Germans are teaming up with the Middle East just like in WWII. We all know how that ended up for them.
How early? You've been saying that for three months now but you've been wrong. For all you know the 50k blocks selling right now are Vyera and they haven't done much.
down, not up! $0.10 before end of year is my guess
A recent well controlled clinical study conducted by Didier Raoult? M.D/Ph.D, et. al in France has shown that 100% of patients that received a combination of HCQ and Azithromycin tested negative and were virologically cured within 6 days of treatment.
Moreover, chloroquine is not listed among the four treatments studied as part of the recently launched European clinical trial piloted by Inserm, which includes 3200 severe hospitalised patients, including 800 French patients.
Chloroquine was ruled out due to the risk of interactions with other medications for common comorbidities in infected patients, and because of possible adverse effects in patients undergoing resuscitation.
Trial included 36 adult patients, 26 received HCQ & 16 controls. Six out of 42 patients meeting inclusion criteria lost to follow up. (All from treatment group: 3 transferred to ICU, 1 death, 1 left hospital, 1 stopped HCQ bc nausea. No control patients lost to follow-up.)
HCQ-treated patients average age 51.2 yrs vs control patients average age of 37.3 yrs. Six patients receiving HCQ received azithromycin on day 1 (unclear how certain patients were selected to receive azithromycin).
Results on Day 6:
-12.5% of control patients virologically cured
-57.1% of HCQ treated patients virologically cured
-100% of HCQ + Azithromycin patients virologically cured
Outstanding Shares - 300,639,710 up from 273 million. Of course these are only the ones the transfer agent knows about.
Today little finance
cydy still looking for drugs to treat it
There are no restrictions on sale of shares, exercise of warrants or sale of shares converted to warrants issued to Vyera.
HIV - Monotherapy Label Extension
from 3/19/2020 Webinar
03:48 Nader Pourhassan - Monotherapy was the first time that the single agent antibody that was self-injectable at home was tested and the results got better and better where the FDA agreed to look at a pivotal clinical trial and consider that for final approval after the first approval so it will be expanded label.
"Look at how many new indications he start and does not stick to one till completion."
Not quite right -
Started with Mono
FDA wanted a combo trial approved first
Started with HIV combo
Finished with HIV combo, FDA changed dosage and wanted additinal data, awaiting finalized BLA submission
Finished Mono, phase 3 interventional
Mono phase 3 pivotal should not be necessary, see my next post (label expansion)
Started GVHD
Stopped GVHD (focus on cancer)
Started GVHD (first patient injected)
Approved for clinical trial in NASH (trial not started)
Started 22 solid tumor clinical trial
Started discussions with China for distribution rights
Discussions ongoing with China, Japan and Taiwan
and it equaled -40%.
This is not happening even with BTD - with this down market unless they show spectacular cancer results
Even though your due diligence is abysmal you should know that leronlimab is not the same as lopinavir and ritonavir. The way that you can tell is that they use differing letters in a different order. I am glad I could be of service to you in rectifying an obvious mistake on your part.
With your claimed shorting of the stock with a rise in share price you're losing.
Being that there have been lies and to many missed deadlines why hasnt a long confronted ceo with these questions?
With 100,000 doses minus our wholesale - at 1/3rd of retail that should be $28 million, at 1/2 of retail it should be $47 million.
Current $1 a share up from .935. Tanking? No wonder you seem confused in regards to where this is going. Up is down and down is up.
Hmmm, JMJ Financial doesn't seem big enough for $100 million.
Another false statement. No promoting has been happening.
Your desperation smells like failure.
I didn’t see you yesterday
Given your track record no worries from me.
For someone not invested you're overly impatient.
What decade was that .77 supposed to happen?
Time to put AGC and Samsung on standby ready to produce leronlimab when sufficient results come in. 2 weeks for Samsung to produce a 600,000+ dose batch and 2-4 weeks for AGC depending on the type of bioreactor they're using.
8 press releases in half a month looks very ________________!
Where's the logic? Vyera isn't going to do a massive stock dump and kill off their one chance at redemption and profitability.
But a Japanese health ministry source suggested the drug was not as effective in people with more severe symptoms. “We’ve given Avigan to 70 to 80 people, but it doesn’t seem to work that well when the virus has already multiplied,” the source told the Mainichi Shimbun.
The same limitations had been identified in studies involving coronavirus patients using a combination of the HIV antiretrovirals lopinavir and ritonavir, the source added.
It makes you wonder how many warrants have been exercised and how much cash the company has gained.
ps. It's always been expected the warrants would be exercised so it's not unexpected dilution.
You don't invest in companies with zero revenue?
based on the information that can be gleaned from their filings